DE69833645T2 - Neue therapeutische kombinationen aus mirtazapin und antipsychotika, zur behandlung oder prophylaxe von psychotischen störungen - Google Patents

Neue therapeutische kombinationen aus mirtazapin und antipsychotika, zur behandlung oder prophylaxe von psychotischen störungen Download PDF

Info

Publication number
DE69833645T2
DE69833645T2 DE69833645T DE69833645T DE69833645T2 DE 69833645 T2 DE69833645 T2 DE 69833645T2 DE 69833645 T DE69833645 T DE 69833645T DE 69833645 T DE69833645 T DE 69833645T DE 69833645 T2 DE69833645 T2 DE 69833645T2
Authority
DE
Germany
Prior art keywords
mirtazapine
haloperidol
treatment
risperidone
sulpiride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69833645T
Other languages
German (de)
English (en)
Other versions
DE69833645D1 (de
Inventor
Louis Christophorus BROEKKAMP
Henricus Hermanus BERENDSEN
Martin Roger PINDER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon NV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Application granted granted Critical
Publication of DE69833645D1 publication Critical patent/DE69833645D1/de
Publication of DE69833645T2 publication Critical patent/DE69833645T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE69833645T 1997-03-27 1998-03-25 Neue therapeutische kombinationen aus mirtazapin und antipsychotika, zur behandlung oder prophylaxe von psychotischen störungen Expired - Lifetime DE69833645T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP97200881 1997-03-27
EP97200881 1997-03-27
EP97202785 1997-09-11
EP97202785 1997-09-11
PCT/EP1998/001920 WO1998043646A1 (en) 1997-03-27 1998-03-25 New therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders

Publications (2)

Publication Number Publication Date
DE69833645D1 DE69833645D1 (de) 2006-04-27
DE69833645T2 true DE69833645T2 (de) 2006-08-24

Family

ID=26146283

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69833645T Expired - Lifetime DE69833645T2 (de) 1997-03-27 1998-03-25 Neue therapeutische kombinationen aus mirtazapin und antipsychotika, zur behandlung oder prophylaxe von psychotischen störungen

Country Status (24)

Country Link
EP (1) EP0969845B1 (enExample)
JP (2) JP4377456B2 (enExample)
KR (1) KR100577865B1 (enExample)
CN (1) CN1226036C (enExample)
AR (1) AR012193A1 (enExample)
AT (1) ATE318604T1 (enExample)
AU (1) AU726194B2 (enExample)
BR (1) BR9808077A (enExample)
CA (1) CA2284551C (enExample)
CZ (1) CZ298105B6 (enExample)
DE (1) DE69833645T2 (enExample)
DK (1) DK0969845T3 (enExample)
ES (1) ES2259207T3 (enExample)
HU (1) HUP0002742A3 (enExample)
ID (1) ID22283A (enExample)
IL (1) IL123716A (enExample)
NO (1) NO994673L (enExample)
NZ (1) NZ337618A (enExample)
PL (1) PL191449B1 (enExample)
PT (1) PT969845E (enExample)
RU (1) RU2222330C2 (enExample)
TR (1) TR199902334T2 (enExample)
TW (1) TW587938B (enExample)
WO (1) WO1998043646A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102012011839A1 (de) * 2012-06-14 2013-12-19 Norbert Müller Verwendung von Interferon-gamma in einem Verfahren zur Behandlung von psychiatrischen Erkrankungen

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
US6280763B1 (en) 1999-05-10 2001-08-28 Pierce Management, Llc Apparatus and method for transdermal delivery of bupropion
FR2797399B1 (fr) * 1999-08-13 2002-10-18 Aventis Pharma Sa Utilisation de la cyamemazine dans le traitement du sevrage aux benzodiazepines
US6350773B1 (en) 1999-12-10 2002-02-26 American Home Products Corporation Therapeutic combinations of (S)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro 7H-1,4-dioxino{2,3-e}indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders
FR2802101B1 (fr) * 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
HUP0204050A3 (en) * 2000-01-19 2004-09-28 Akzo Nobel Nv Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone
US6495154B1 (en) * 2000-11-21 2002-12-17 Vivus Inc. On demand administration of clomipramine and salts thereof to treat premature ejaculation
JP2004518699A (ja) 2001-02-06 2004-06-24 アストラゼネカ・アクチエボラーグ クエチアピンを用いた物質乱用の治療方法
EP1795199A3 (en) * 2001-02-06 2007-07-25 AstraZeneca AB Quetiapine for the treatment of substance dependence or substance abuse
RU2232574C2 (ru) * 2002-04-05 2004-07-20 Новосибирский институт органической химии им. Н.Н.Ворожцова СО РАН Лекарственное средство для лечения различных форм депрессий "флуоглизин"
US20050095292A1 (en) 2003-10-29 2005-05-05 Wyeth Sustained release pharmaceutical compositions
DK1541197T3 (da) * 2003-12-02 2009-06-15 Pharmaneuroboost N V Anvendelse af pipamperon og en SNDRI, SNRI eller SSRI til behandling af humörsvingninger eller angstlidelser
US7884096B2 (en) 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
CA2547639A1 (en) * 2003-12-02 2005-06-16 B&B Beheer Nv Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
US7855195B2 (en) 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP1547650A1 (en) * 2003-12-02 2005-06-29 B & B Beheer NV Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
CN1968706A (zh) 2004-06-03 2007-05-23 霍夫曼-拉罗奇有限公司 用顺铂和egfr－抑制剂治疗
JP5001271B2 (ja) * 2006-06-09 2012-08-15 大日本住友製薬株式会社 新規テープ製剤
JOP20120083B1 (ar) * 2011-04-05 2021-08-17 Otsuka Pharma Co Ltd توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns
RU2509560C1 (ru) * 2013-03-22 2014-03-20 Общество С Ограниченной Ответственностью "Валента-Интеллект" Новые терапевтические комбинации миртазапина для применения при болевых расстройствах

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2410821A1 (de) * 1974-03-07 1975-09-18 Hoechst Ag Pharmazeutische kombinationspraeparate mit psychotroper wirkung und verfahren zu ihrer herstellung
CA1327008C (en) * 1988-01-15 1994-02-15 Walter Merz Anti-psychotic imidazobenzodiazepine
EP0431663B1 (en) * 1989-12-06 1994-01-12 Akzo Nobel N.V. Stabilized solutions of psychotropic agents
FI111367B (fi) * 1991-02-04 2003-07-15 Aventis Pharma Inc Menetelmä terapeuttisesti käyttökelpoisten N-(aryylioksialkyyli)heteroaryyli-8-atsabisyklo[3.2.1]oktaanijohdannaisten valmistamiseksi ja menetelmässä käytetyt välituotteet
ZA935078B (en) * 1992-07-15 1994-02-07 Nicolaas Johannes Jaco Loetter Pharmaceutical composition
RU2062114C1 (ru) * 1992-09-30 1996-06-20 Московский научно-исследовательский институт психиатрии МЗ РФ Способ лечения эндогенных психозов
PT669128E (pt) * 1992-11-17 2000-06-30 Yoshitomi Pharmaceutical Micro-esfera de libertacao sustentada contendo antipsicoticos e processo para produzir a mesma
JPH07242669A (ja) * 1994-03-07 1995-09-19 Akikazu Ogawa 四環系とブチロフェノン誘導体を化学結合した化合物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102012011839A1 (de) * 2012-06-14 2013-12-19 Norbert Müller Verwendung von Interferon-gamma in einem Verfahren zur Behandlung von psychiatrischen Erkrankungen
DE102012011839B4 (de) 2012-06-14 2018-03-22 Norbert Müller Verwendung von Interferon-gamma in einem Verfahren zur Behandlung von psychiatrischen Erkrankungen

Also Published As

Publication number Publication date
KR20010005677A (ko) 2001-01-15
HUP0002742A2 (hu) 2001-05-28
ID22283A (id) 1999-09-30
IL123716A0 (en) 1998-12-06
NZ337618A (en) 2000-06-23
AR012193A1 (es) 2000-09-27
NO994673D0 (no) 1999-09-24
PT969845E (pt) 2006-05-31
PL335890A1 (en) 2000-05-22
RU2222330C2 (ru) 2004-01-27
CZ298105B6 (cs) 2007-06-27
CA2284551C (en) 2007-06-12
CA2284551A1 (en) 1998-10-08
BR9808077A (pt) 2000-03-08
CN1251526A (zh) 2000-04-26
KR100577865B1 (ko) 2006-05-10
TW587938B (en) 2004-05-21
EP0969845A1 (en) 2000-01-12
ES2259207T3 (es) 2006-09-16
EP0969845B1 (en) 2006-03-01
TR199902334T2 (xx) 2000-01-21
NO994673L (no) 1999-11-17
JP2009280596A (ja) 2009-12-03
IL123716A (en) 2001-03-19
AU7213998A (en) 1998-10-22
HUP0002742A3 (en) 2003-03-28
DK0969845T3 (da) 2006-06-19
PL191449B1 (pl) 2006-05-31
CZ343199A3 (cs) 2000-04-12
WO1998043646A1 (en) 1998-10-08
ATE318604T1 (de) 2006-03-15
DE69833645D1 (de) 2006-04-27
CN1226036C (zh) 2005-11-09
AU726194B2 (en) 2000-11-02
JP4377456B2 (ja) 2009-12-02
JP5023315B2 (ja) 2012-09-12
HK1023293A1 (en) 2000-09-08
JP2001521497A (ja) 2001-11-06

Similar Documents

Publication Publication Date Title
DE69833645T2 (de) Neue therapeutische kombinationen aus mirtazapin und antipsychotika, zur behandlung oder prophylaxe von psychotischen störungen
DE60009346T2 (de) Buprenorphin enthaltende analgetische zusammensetzungen
US6150353A (en) Therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders
CA1048932A (en) Composition for treating schizophrenia
EP1265615A2 (de) Neue kombination nichtsedierender antihistaminika mit substanzen, die die leukotrienwirkung beeinflussen, zur behandlung der rhinitis/konjunktivitis
DE60009697T2 (de) Verwendung von 1-[4-(5-cyanoindol-3yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazin und dessen physiologisch akzeptablen salzen zur behandlung von bipolaren krankheiten und manie
EP1140082A1 (de) Kombination von cerivastatin und fibraten
EP2026793A2 (en) Use of escitalopram for improving cognition
US3978216A (en) Method for treating schizophrenia and method and composition for potentiating neuroleptic drugs
AU745759B2 (en) Application of substituted aminomethyl chromans in order to prevent neural degeneration and to promote neural regeneration
DE60111025T2 (de) Verwendung von Topiramat zur Behandlung und Diagnostizierung von Atemstörungen während des Schlafens und Mittel zur Durchführung der Behandlung und Diagnose
US4138484A (en) Method for treating schizophrenia and method and composition for potentiating neuroleptic drugs
US4129652A (en) Method for potentiating neuroleptic drugs
US4084000A (en) Method of treating schizophrenia
DE60204694T2 (de) Kombinationstherapie zur behandlung von herzinsuffizienz
DE69431986T2 (de) Verwendung von granisetron zur behandlung von postoperativer übelkeit und erbrechen
DE69522764T2 (de) Verwendung vom einem Bicycloheptan-Derivat
DE60125062T2 (de) Quetiapin zur Behandlung der Dyskinesie in nicht-psychotischen Patienten
US4886815A (en) Treatment and prevention of retinal edema with dopaminergic antagonists
DE69129623T2 (de) Behandlungsverfahren für therapiewiderstehende schizophrenie mit amperozide
DE60319399T2 (de) Pharmazeutische kombination von tenatoprazole und einem histamin-h2-rezeptor antagonisten
DE10163421A1 (de) Verwendung von (+)-(1S,2S)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol als Antiemetikum
US4886795A (en) Treatment and prevention of retinal edema with dopaminergic antagonists
US20040152722A1 (en) Use of phencynonate hydrochloride
AT402691B (de) Verwendung von galanthamin zum herstellen von arzneimitteln zur behandlung von trisomie 21 oder verwandter trisomie-syndrome

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: N.V. ORGANON, OSS, NL

R082 Change of representative

Ref document number: 969845

Country of ref document: EP

Representative=s name: WUESTHOFF & WUESTHOFF PATENT- UND RECHTSANWAEL, DE